INSIDE INFORMATION: The preliminary result of the rights issue in Acarix AB (”Acarix” or the
“Company”), in which the subscription period ended on 8 September 2020, indicates that a total of
105,414,911 shares have been subscribed or registered for subscription in the rights issue, which
corresponds to approximately 122 percent of the rights issue. Thus, the preliminary results show
that the rights issue has been oversubscribed.
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, email@example.com) is Certified Advisor of Acarix.